188 related articles for article (PubMed ID: 38542066)
21. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
[TBL] [Abstract][Full Text] [Related]
22. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88
Deng T; Zhang S; Xiao M; Gu J; Huang L; Zhou X
Cancer Med; 2024 Feb; 13(4):e7005. PubMed ID: 38457222
[TBL] [Abstract][Full Text] [Related]
23. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas.
De Paepe P; Achten R; Verhoef G; Wlodarska I; Stul M; Vanhentenrijk V; Praet M; De Wolf-Peeters C
J Clin Oncol; 2005 Oct; 23(28):7060-8. PubMed ID: 16129841
[TBL] [Abstract][Full Text] [Related]
24. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
[TBL] [Abstract][Full Text] [Related]
25. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL; van Eijk R; Böhringer S; van Wezel T; Raghoo R; Ruano D; Jansen PM; Briaire-de Bruijn I; de Groot FA; Kleiverda K; Te Boome L; Terpstra V; Levenga H; Nicolae A; Posthuma EFM; Focke-Snieders I; Hardi L; den Hartog WCE; Bohmer LH; Hogendoorn PCW; van den Berg A; Diepstra A; Nijland M; Lugtenburg PJ; Kersten MJ; Pals ST; Veelken H; Bovée JVMG; Cleven AHG; Vermaat JSP
Blood Adv; 2021 Oct; 5(19):3760-3775. PubMed ID: 34478526
[TBL] [Abstract][Full Text] [Related]
26. Non-germinal center B-cell subtype of pediatric diffuse large B-cell lymphoma in Japan: A retrospective cohort study.
Hori D; Kobayashi R; Nakazawa A; Iwafuchi H; Klapper W; Osumi T; Ohk K; Sekimizu M
Pediatr Blood Cancer; 2023 May; 70(5):e30279. PubMed ID: 36860130
[TBL] [Abstract][Full Text] [Related]
27. The altered metabolic pathways of diffuse large B-cell lymphoma not otherwise specified.
Rodrigues-Fernandes CI; Martins-Chaves RR; Vitório JG; Duarte-Andrade FF; Pereira TDSF; Soares CD; Moreira VR; Lebron YAR; Santos LVS; Lange LC; Canuto GAB; Gomes CC; de Macedo AN; Pontes HAR; Burbano RMR; Martins MD; Pires FR; Mesquita RA; Gomez RS; Santos-Silva AR; Lopes MA; Vargas PA; Fonseca FP
Leuk Lymphoma; 2023; 64(11):1771-1781. PubMed ID: 37462418
[TBL] [Abstract][Full Text] [Related]
28. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
29. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
30. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features.
Eriksen PRG; de Groot F; Clasen-Linde E; de Nully Brown P; de Groen R; Melchior LC; Maier AD; Minderman M; Vermaat JSP; von Buchwald C; Pals ST; Heegaard S
Blood Adv; 2024 Apr; 8(8):1946-1957. PubMed ID: 38324724
[TBL] [Abstract][Full Text] [Related]
31. EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK/STAT (STAT3) pathway mutations and unique clinicopathologic features.
Chapman JR; Bouska AC; Zhang W; Alderuccio JP; Lossos IS; Rimsza LM; Maguire A; Yi S; Chan WC; Vega F; Song JY
Br J Haematol; 2021 Sep; 194(5):870-878. PubMed ID: 34272731
[TBL] [Abstract][Full Text] [Related]
32. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW
Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166
[TBL] [Abstract][Full Text] [Related]
33. Impact of Double Expression of C-MYC/BCL2 Protein and Cell of Origin Subtypes on the Outcome among Patients with Diffuse Large B-Cell Lymphoma: a Single Asian Center Experience.
Teoh CS; Lee SY; Chiang SK; Chew TK; Goh AS
Asian Pac J Cancer Prev; 2018 May; 19(5):1229-1236. PubMed ID: 29801406
[TBL] [Abstract][Full Text] [Related]
34. Utility of reverse transcriptase - Multiplex ligation-dependant probe amplification (RT-MLPA) in the molecular classification of Diffuse Large B cell lymphoma (DLBCL) by cell-of-origin (COO).
Dcunha N; Sakhti D; Sigamani E; Chandramohan J; Korula A; George B; Manipadam MT; Pai R
Indian J Pathol Microbiol; 2023; 66(4):714-719. PubMed ID: 38084521
[TBL] [Abstract][Full Text] [Related]
35. Leukemic presentation and progressive genomic alterations of MCD/C5 diffuse large B-cell lymphoma (DLBCL).
Kim PM; Nejati R; Lu P; Thakkar D; Mackrides N; Dupoux V; Nakhoda S; Baldwin DA; Pei J; Dave SS; Wang YL; Wasik MA
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37730436
[TBL] [Abstract][Full Text] [Related]
36. A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma.
Skacel M; Ross CW; Hsi ED
Histopathology; 2000 Jul; 37(1):10-8. PubMed ID: 10931213
[TBL] [Abstract][Full Text] [Related]
37. Evidence-based review of genomic aberrations in diffuse large B cell lymphoma, not otherwise specified (DLBCL, NOS): Report from the cancer genomics consortium lymphoma working group.
Yenamandra AK; Smith RB; Senaratne TN; Kang SL; Fink JM; Corboy G; Hodge CA; Lu X; Mathew S; Crocker S; Fang M
Cancer Genet; 2022 Nov; 268-269():1-21. PubMed ID: 35970109
[TBL] [Abstract][Full Text] [Related]
38. Value of GCET1, HGAL (GCET2), and LMO2 in the Determination of Germinal Center Phenotype in Diffuse Large B-cell Lymphoma.
Berker N; Yeğen G; Özlük Y; Doğan Ö
Turk J Haematol; 2023 Aug; 40(3):162-173. PubMed ID: 37519110
[TBL] [Abstract][Full Text] [Related]
39. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
40. Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.
Mareschal S; Pham-Ledard A; Viailly PJ; Dubois S; Bertrand P; Maingonnat C; Fontanilles M; Bohers E; Ruminy P; Tournier I; Courville P; Lenormand B; Duval AB; Andrieu E; Verneuil L; Vergier B; Tilly H; Joly P; Frebourg T; Beylot-Barry M; Merlio JP; Jardin F
J Invest Dermatol; 2017 Sep; 137(9):1984-1994. PubMed ID: 28479318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
